Bifogade filer
Kurs
+21,65%
Kalender
Est. tid* | ||
2026-03-03 | 08:30 | Bokslutskommuniké 2025 |
2025-11-04 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-12 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-14 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
2025-05-13 | - | Årsstämma |
2025-05-06 | - | Kvartalsrapport 2025-Q1 |
2025-03-04 | - | Bokslutskommuniké 2024 |
2024-11-05 | - | Kvartalsrapport 2024-Q3 |
2024-08-13 | - | Kvartalsrapport 2024-Q2 |
2024-05-15 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
2024-05-14 | - | Årsstämma |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-03-05 | - | Bokslutskommuniké 2023 |
2023-10-17 | - | Kvartalsrapport 2023-Q3 |
2023-08-15 | - | Kvartalsrapport 2023-Q2 |
2023-05-25 | - | Kvartalsrapport 2023-Q1 |
2023-05-17 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
2023-05-16 | - | Årsstämma |
2023-03-07 | - | Bokslutskommuniké 2022 |
2022-11-22 | - | Kvartalsrapport 2022-Q3 |
2022-08-16 | - | Kvartalsrapport 2022-Q2 |
2022-05-25 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
2022-05-24 | - | Årsstämma |
2022-05-03 | - | Kvartalsrapport 2022-Q1 |
2022-03-08 | - | Bokslutskommuniké 2021 |
2021-11-02 | - | Kvartalsrapport 2021-Q3 |
2021-08-17 | - | Kvartalsrapport 2021-Q2 |
2021-05-25 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
2021-05-24 | - | Årsstämma |
2021-05-04 | - | Kvartalsrapport 2021-Q1 |
2021-03-08 | - | Bokslutskommuniké 2020 |
2020-11-11 | - | Kvartalsrapport 2020-Q3 |
2020-08-18 | - | Kvartalsrapport 2020-Q2 |
2020-05-20 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
2020-05-19 | - | Årsstämma |
2020-05-13 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-11-12 | - | Kvartalsrapport 2019-Q3 |
2019-08-12 | - | Kvartalsrapport 2019-Q2 |
2019-05-09 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
2019-05-08 | - | Årsstämma |
2019-05-08 | - | Kvartalsrapport 2019-Q1 |
2019-03-19 | - | Extra Bolagsstämma 2019 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-15 | - | Kvartalsrapport 2018-Q3 |
2018-08-15 | - | Kvartalsrapport 2018-Q2 |
2018-05-15 | - | Extra Bolagsstämma 2018 |
2018-05-15 | - | Kvartalsrapport 2018-Q1 |
2018-03-01 | - | X-dag ordinarie utdelning CMOTEC B 0.00 SEK |
2018-02-28 | - | Årsstämma |
2018-01-30 | - | Bokslutskommuniké 2017 |
2017-05-31 | - | Extra Bolagsstämma 2017 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Scandinavian ChemoTech AB announces today that the Company has received approval from the European Patent Office. The final injunction for this patent application was announced in a press release on the 3[d ]of February 2021. The examiner announces that the approval will be published 7[th] of July 2021.
The patent covers a specially developed electrode as well as unique dynamic properties, which already exist in the TSE platform, intended to treat tumours without damaging important parts of organs and tissues such as nerve pathways and blood vessels. This is of utmost importance in the treatment of, among other things, the spine and prostate.
This innovation provides improved pain control when using the Company's DEEPC™ (Dynamic Electro Enhanced Pain Control) device for IQwave™, for the delivery of electrical pulses to the desired body part.
"A few weeks ago, ChemoTech received CE marking for its medical technology product and system for cancer treatment. It is very gratifying to now also have this EU patent approved, which shows the wide technical range of ChemoTech's TSE platform. We are now expanding the patent protection to also include pain relief, which is a very important part of cancer treatment. This approval gives ChemoTech's human and veterinary operations both the important protection needed for both the commercial establishment in the EU and that it attracts potential partners for distribution and / or licensing agreements. " - says Mohan Frick, CEO and author of this patent together with Prof B Persson
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se